Africa UN Knowledge Hub for COVID-19

A single dose of the COVID-19 vaccine made by either Pfizer or AstraZeneca cuts a person’s risk of transmitting SARS-CoV-2 to their closest contacts by as much as half, according to an analysis of more than 365,000 households in the United Kingdom.

When Christina Brennan initially planned a clinical trial to test the use of famotidine for treating mild COVID-19, she wrote a protocol that involved participants occasionally coming in for lab work at an internal medicine clinic. Enrollment in trials run by Brennan and her colleagues on hospitalized COVID-19 patients was waning following last spring’s surge, so she’d shifted her focus to studying COVID-19 patients who were fighting the disease at home. But in speaking with the clinic’s doctors last summer, she learned that patients who had tested positive for SARS-CoV-2 would not be allowed in the clinic of the nonprofit provider Northwell Health, New York’s largest healthcare system. 

In voting shadowed by a catastrophic surge in coronavirus cases, the party of Prime Minister Narendra Modi lost a key state election. International aid has begun flowing into the country.

The backroom scientists and clinician-researchers who actually enabled the saving of so many lives often go unmentioned

Two years into the pandemic, the COVID-19 drugs pipeline is primed to pump out novel treatments — and fresh uses for familiar therapies.

AbbVie (NYSE: ABBV) and Scripps Research announced a global collaboration to develop potential novel, direct-acting antiviral treatments for COVID-19.

The pandemic has led to vaccine advancements, new insights on the way respiratory viruses spread and a better understanding of the immune system

Speeding up development of new vaccines won’t help much in the next pandemic, unless world leaders work faster to roll out vaccination globally.

Versions of Omicron are highly transmissible and less susceptible to vaccines, but seem to cause less severe illness and fewer deaths among those who are immunized.

Supply shortages and limits on research leave low- and middle-income countries struggling to access Pfizer’s COVID-19 antiviral.